相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer
Rico D. Bense et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer
Rico D. Bense et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Clinical relevance of host immunity in breast cancer: from TILs to the clinic
Peter Savas et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
The genomic landscape of breast cancer and its interaction with host immunity
Stephen Luen et al.
BREAST (2016)
Retrospective analysis of molecular scores for the prediction of distant recurrence according to baseline risk factors
Ivana Sestak et al.
BREAST CANCER RESEARCH AND TREATMENT (2016)
Spatial Heterogeneity in the Tumor Microenvironment
Yinyin Yuan
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2016)
Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2-Positive and Triple-Negative Primary Breast Cancers
Carsten Denkert et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Beyond immune density: critical role of spatial heterogeneity in estrogen receptor-negative breast cancer (vol 28, pg 1621, 2015)
Sidra Nawaz et al.
MODERN PATHOLOGY (2015)
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
Sandip Pravin Patel et al.
MOLECULAR CANCER THERAPEUTICS (2015)
The prognostic landscape of genes and infiltrating immune cells across human cancers
Andrew J. Gentles et al.
NATURE MEDICINE (2015)
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
R. Salgado et al.
ANNALS OF ONCOLOGY (2015)
Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study
M. V. Dieci et al.
ANNALS OF ONCOLOGY (2014)
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
S. Loi et al.
ANNALS OF ONCOLOGY (2014)
Association between CD8+T-cell infiltration and breast cancer survival in 12 439 patients
H. R. Ali et al.
ANNALS OF ONCOLOGY (2014)
Effect of Aromatase Inhibition on Functional Gene Modules in Estrogen Receptor-Positive Breast Cancer and Their Relationship with Antiproliferative Response
Qiong Gao et al.
CLINICAL CANCER RESEARCH (2014)
Elevated expression of TANK-binding kinase 1 enhances tamoxifen resistance in breast cancer
Congwen Wei et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Molecular Profiling of Aromatase Inhibitor-Treated Postmenopausal Breast Tumors Identifies Immune-Related Correlates of Resistance
Anita K. Dunbier et al.
CLINICAL CANCER RESEARCH (2013)
CD4+ follicular helper T cell infiltration predicts breast cancer survival
Chunyan Gu-Trantien et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98
Sherene Loi et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Factors Predicting Late Recurrence for Estrogen Receptor-Positive Breast Cancer
Ivana Sestak et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Quantitative Image Analysis of Cellular Heterogeneity in Breast Tumors Complements Genomic Profiling
Yinyin Yuan et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
The immune contexture in human tumours: impact on clinical outcome
Wolf Herman Fridman et al.
NATURE REVIEWS CANCER (2012)
Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast Cancer
Jack Cuzick et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor-Positive Breast Cancer
Torsten O. Nielsen et al.
CLINICAL CANCER RESEARCH (2010)
Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
Carsten Denkert et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study
Mitch Dowsett et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
International Web-based consultation on priorities for translational breast cancer research
Mitch Dowsett et al.
BREAST CANCER RESEARCH (2007)
Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling
MPHM Jansen et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
S Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
分享论文
